Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aticaprant (Primary)
  • Indications Smoking withdrawal
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Avalo Therapeutics; Cerecor; Janssen Research & Development

Most Recent Events

  • 03 Jan 2017 Status changed from active, no longer recruiting to completed.
  • 05 Dec 2016 According to a Cerecor media release, the company intends to present additional data from this trial at scientific meetings in 2017.
  • 05 Dec 2016 Primary endpoint has not been met. (Latency), as reported in a Cerecor media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top